Cargando…

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections

BACKGROUND: Dalbavancin (DAL) is a long-acting lipoglycopeptide with activity against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). This study investigates DAL as sequential therapy in S. aureus bloodstream infections (BSIs). METHODS: We conducted a retrospective cohort st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molina, Kyle C, Lunowa, Cali, Lebin, Madelyn, Segerstrom Nunez, Andrea, Azimi, Sara F, Krsak, Martin, Mueller, Scott W, Miller, Matthew A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314917/ https://www.ncbi.nlm.nih.gov/pubmed/35899276 http://dx.doi.org/10.1093/ofid/ofac335

Ejemplares similares

850. External Validation of the Methicillin-Resistant Staphylococcus aureus Bacteremia Score
por: Boyle, Ellen, et al.
Publicado: (2020)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

Low Diversity in Nasal Microbiome Associated With Staphylococcus aureus Colonization and Bloodstream Infections in Hospitalized Neonates
por: Zhao, Ni, et al.
Publicado: (2021)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Zasowski, Evan J, et al.
Publicado: (2021)

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

Characteristics and Outcomes of Staphylococcus aureus Bloodstream Infection Originating From the Urinary Tract: A Multicenter Cohort Study
por: Grillo, Sara, et al.
Publicado: (2020)

Global Differences in the Management of Staphylococcus aureus Bacteremia: No International Standard of Care
por: Westgeest, Annette C, et al.
Publicado: (2023)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Patients’ Experiences With Staphylococcus aureus and Gram-Negative Bacterial Bloodstream Infections: Results From Cognitive Interviews to Inform Assessment of Health-Related Quality of Life
por: King, Heather A, et al.
Publicado: (2021)

Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections—A Single-Center Observational Study
por: Hamad, Yasir, et al.
Publicado: (2020)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus
por: Jacob, Benjamin, et al.
Publicado: (2021)

Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus
por: Scutera, Sara, et al.
Publicado: (2023)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients
por: Novak, Alison R, et al.
Publicado: (2021)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
por: Rappo, Urania, et al.
Publicado: (2018)

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study
por: Alosaimy, Sara, et al.
Publicado: (2021)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2019)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates
por: Bongiorno, Dafne, et al.
Publicado: (2020)

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
por: Hoyt, Aaron K., et al.
Publicado: (2023)

Impact of an Unsolicited, Standardized Form–Based Antimicrobial Stewardship Intervention to Improve Guideline Adherence in the Management of Staphylococcus aureus Bacteremia
por: Remtulla, Shahileen, et al.
Publicado: (2019)

Staphylococcus aureus Bacteremia in Pediatric Patients: Uncovering a Rural Health Challenge
por: Whittington, Kyle J, et al.
Publicado: (2023)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Management of Staphylococcus aureus Bloodstream Infections
por: Kimmig, Aurelia, et al.
Publicado: (2021)

Effect of Clinically Uninfected Orthopedic Implants and Pacemakers/AICDs in Low-Risk Staphylococcus aureus Bloodstream Infection on Crude Mortality Rate: A Post Hoc Analysis of a Large Cohort Study
por: Kaasch, Achim J, et al.
Publicado: (2019)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study
por: Tamma, Pranita D, et al.
Publicado: (2022)

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial
por: Hassanzadeh, Hamid, et al.
Publicado: (2023)

The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Miller, William R, et al.
Publicado: (2018)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Benefit of Echocardiography in Patients With Staphylococcus aureus Bacteremia at Low Risk of Endocarditis
por: Heriot, George S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p9c26mgapohs0su5qprjq451ct